Marketing: Page 12
-
Jacob Bell/BioPharma Dive
Incyte secures second approval for targeted cancer drug
Sold as Pemazyre, the drug, which blocks well-known cancer proteins known as FGFRs, is now also cleared for use in certain patients with very rare and aggressive blood cancers.
By Jacob Bell • Aug. 29, 2022 -
Getty Images
Sponsored by Worldwide Clinical TrialsPsychedelic clinical trials: What sponsors should know when designing new protocols
With regulators and lawmakers seemingly on board, sponsors have more opportunities than ever to pursue clinical research in this high-velocity area.
Aug. 29, 2022 -
Explore the Trendline➔
Brian Tucker / BioPharma Dive/BioPharma Dive
TrendlineCommercialization
New drugs for obesity are becoming blockbusters, while Trump administration pressure is reshaping pharma marketing strategies ahead of looming patent cliffs.
By BioPharma Dive staff -
Gabriel Kuchta via Getty Images
Moderna sues Pfizer, BioNTech over COVID-19 vaccine technology
The biotech claims its rivals’ vaccine Comirnaty, one of the world’s top-selling pharmaceutical products, infringes on two patents covering its messenger RNA technology.
By Jonathan Gardner • Aug. 26, 2022 -
Novartis begins plans to spin off generic drug business
After reviewing multiple options including a possible sale, the Swiss drugmaker said spinning off Sandoz would give the division “greater freedom to operate” and capitalize on newly growing sales.
By Jonathan Gardner • Aug. 25, 2022 -
Permission granted by Gilead Sciences
Gilead breaks through with first approval for new HIV drug
European authorities cleared Gilead’s long-acting shot for patients whose HIV infection is resistant to other drugs. An FDA decision is expected by December.
By Jonathan Gardner • Aug. 22, 2022 -
Permission granted by Akili Interactive
Digital medicine company Akili gets cold market reception after blank-check merger
After spiking on news of the merger’s close, shares in the ADHD treatment developer fell sharply in trading.
By Elise Reuter • Updated Aug. 23, 2022 -
National Institute of Allergy and Infectious Diseases. (2020). "Novel Coronavirus SARS-CoV-2" [Image]. Retrieved from Flickr.
US plans shift to private market sales of COVID-19 vaccines, drugs
The federal government will begin the transition as early as this fall, clearing the way for drugmakers to control sales and distribution of their medicines.
By Christopher Newman • Aug. 17, 2022 -
Gabriel Kuchta via Getty Images
UK approves Moderna’s two-pronged COVID-19 booster
Britain’s drug regulator is the first public health authority to clear a vaccine designed to fight omicron as well as the original strain of the virus.
By Jonathan Gardner • Aug. 15, 2022 -
Jeenah Moon via Getty Images
Pfizer’s new pneumococcal vaccine meets study goal in children
Pfizer, which competes with Merck in this market, plans to ask the FDA for an expanded approval of its 20-valent shot later this year.
By Delilah Alvarado • Aug. 12, 2022 -
Drew Angerer via Getty Images
GSK, Pfizer, Sanofi shares drop amid Zantac litigation concerns
The companies could face liability related to their sales of the heartburn drug, which was withdrawn from the market in the U.S. and other countries after impurities related to a likely carcinogen were detected.
By Ned Pagliarulo • Updated Aug. 11, 2022 -
Getty Images
Coherus wins FDA approval for second Lucentis biosimilar, its third drug
The biotech company secured a valuable interchangeable designation for the copycat medicine, which it plans to launch later this year.
By Kristin Jensen • Aug. 3, 2022 -
iStock via Getty Images
With new data, Roche takes step toward more convenient cancer immunotherapy
The pharma claimed Phase 3 study success for a subcutaneous version of its drug Tecentriq, a strategy it and rivals Merck and Bristol Myers could use to extend the market life of their lucrative drugs.
By Ben Fidler • Aug. 2, 2022 -
Lisa Maree Williams via Getty Images
AbbVie cancer drug sales fall as AstraZeneca competitor gains ground
Imbruvica, long one of AbbVie’s top-selling medicines, has ceded market share in treating chronic lymphocytic leukemia to AstraZeneca’s Calquence.
By Ned Pagliarulo • July 29, 2022 -
Dan Kitwood via Getty Images
Pfizer sales of COVID-19 vaccine, pill beat forecasts as company prepares for future waves
The company plans to ready a booster shot by the fall that targets the BA.4 and BA.5 strains that are currently most prevalent in the U.S. and other countries.
By Christopher Newman • Updated July 28, 2022 -
Courtesy of Teva Pharmaceutical
Teva reaches deal in principle to settle opioid lawsuits for over $4B
The generics maker joins other pharmaceutical companies attempting to resolve litigation over their alleged contributions to the opioid epidemic.
By Kristin Jensen • July 27, 2022 -
Amazon will see you now: reading between the lines of the One Medical acquisition
The deal’s near-term effects might not be large, but Amazon’s acquisition still threaten’s One Medical’s primary care competitors and others seeking a greater slice of the market, experts said.
By Rebecca Pifer Parduhn • July 25, 2022 -
Sean Gallup via Getty Images
EU speeds approval of monkeypox vaccine as WHO declares public health emergency
Vaccine maker Bavarian Nordic said it is meeting demand for its shot with production capacity of 30 million doses a year.
By Christopher Newman • July 25, 2022 -
Amazon to buy One Medical for $3.9B
The all-cash deal for the San Francisco-based company follows months of speculation about a potential acquisition, but Amazon as the buyer comes as a surprise.
By Rebecca Pifer Parduhn • July 21, 2022 -
Jessica McGowan/Getty Images via Getty Images
CDC backs Novavax's protein-based vaccine for COVID-19
Health officials argue a new type of shot could help to persuade unvaccinated people, although some surveys suggest that might not be the case.
By Delilah Alvarado • July 20, 2022 -
Getty Images
Ultragenyx sells rare disease drug royalties to Canadian pension fund
In exchange for $500 million, the fund, called OMERS, will get a 30% royalty on future sales of Ultragenyx’s drug Crysvita in the U.S. and Canada, where it’s approved to treat two rare conditions.
By Jacob Bell • July 15, 2022 -
Getty Images
Royalty Pharma buys rights to top-selling GSK drug in pair of deals
The prolific biopharma dealmaker is paying Theravance $1.1 billion and Innoviva $282 million to acquire rights to royalties on GSK’s asthma and COPD drug Trelegy Ellipta.
By Kristin Jensen • July 14, 2022 -
Getty / Edited by BioPharma Dive
BioMarin's hemophilia gene therapy recommended for approval in Europe
The decision brings what could be the first approved hemophilia gene therapy, Roctavian, closer to market, after a series of regulatory setbacks that have delayed its arrival.
By Jacob Bell • June 24, 2022 -
Getty Images
Amylyx's ALS drug gets approved in Canada
The Massachusetts-based biotech is awaiting a decision in the U.S., where the FDA recently extended its review after agency advisers narrowly voted against the treatment.
By Jacob Bell • June 13, 2022 -
Permission granted by Fizkes, OM1
Sponsored by OM1Real-world data: A health equity lens for research
Arising from the circumstances in which people grow, live, work and age, and the systems put in place to deal with illness, these health inequities are avoidable.
By Jessica Paulus, ScD, Senior Director, Epidemiology, OM1 • June 13, 2022 -
Carol Highsmith. (2005). "Apex Bldg." [Photo]. Retrieved from Wikimedia Commons.
FTC to investigate CVS Caremark, others in probe of PBM business practices
The decision to launch an inquiry reversed a vote earlier this year, when FTC commissioners had deadlocked over whether to look into the drug pricing middlemen.
By Rebecca Pifer Parduhn • June 7, 2022
Previous
